Perseus Proteomics, Inc. (JP:4882) has launched an replace.
Perseus Proteomics, Inc. has introduced the acceptance of its analysis for presentation on the EANM ’24 Congress, showcasing the preclinical success of PPMX-T002, a radioisotope labelled antibody for stable most cancers therapy. The corporate’s analysis signifies the antibody, now utilizing the alpha emitter Actinium 225, is more practical than the earlier beta emitter in treating human pancreatic most cancers cells in mice.
For additional insights into JP:4882 inventory, take a look at TipRanks’ Inventory Evaluation web page.
